US FDA approves atezolizumab plus chemotherapy for metastatic NSCLC
It has been announced that the US FDA has approved the combination of Tecentriq® (atezolizumab) plus chemotherapy (nab-paclitaxel and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) patients with no EGFR or ALK genomic tumor aberrations.The approval follows positive data from the Phase III IMpower130 clinical trial. This multicenter, open-label, randomized study enrolled 724 individuals who were randomized (2:1) to receive atezolizumab plus carboplatin and nab-paclitaxel (Arm A), or carboplatin and nab-paclitaxel (Arm B, control arm). Find out more about IMpower130 here. The trial demonstrated that atezolizumab plus chemotherapy increased median overall survival compared with...